APOL1 genotype, blood pressure, and survival in African Americans with nondiabetic nephropathy

详细信息    查看全文

• 作者：Todd W. Robinson¹ ; Barry I. Freedman¹ ; ^{bfreedma@wakehealth.edu}
• 刊名：Kidney International
• 出版年：2017
• 出版时间：February 2017
• 年：2017
• 卷：91
• 期：2
• 页码：276-278
• 全文大小：521 K
• 卷排序：91

文摘

Several landmark trials have assessed the effects of aggressive hypertension control on the progression of nondiabetic chronic kidney disease. Results generally have been disappointing. With the realization that lowering blood pressure, including with renin-angiotensin system blockade, failed to reliably prevent end-stage kidney disease, studies now are analyzing longer-term effects of hypertension control on survival in chronic kidney disease. This commentary reviews the current findings and extends the discussion to apolipoprotein L1 gene by blood pressure (or gene by environment) interactions.